Controlled temperatures in cold preservation provides safe heart transplantation results.
SherpaPak
controlled cold preservation
heart transplantation
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
01
11
2021
received:
08
10
2021
accepted:
10
11
2021
pubmed:
22
1
2022
medline:
4
3
2022
entrez:
21
1
2022
Statut:
ppublish
Résumé
We aimed to investigate the short-term outcomes of heart transplant patients who underwent SherpaPak™ donor organ preservation. We prospectively collected the data of patients who underwent heart transplantation using SherpaPak™ system for donor organ transportation from February 2020 to March 2021. Donor and recipient demographic data, preoperative and postoperative echocardiographic and hemodynamic parameters, total ischemic time and SherpaPak temperatures, vasoactive inotropic scores (VIS), primary graft dysfunction (PGD) status, intensive care unit stay, complications, and mortality during follow-up were assessed. A total of 39 consecutive heart transplant patients with SherpaPak system were included in the study. The mean donor age was 32.2 ± 6.7 (range: 16-46). The mean recipient age was 57.5 ± 12 (range: 19-73). The mean preoperative ejection fraction (EF) was 23.7 ± 15.4 (range: 5-75). All recipients underwent a standard bicaval technique for orthotopic heart implantation. The mean total ischemic time was 230.1 ± 41 (range: 149-342) min. The mean Sherpa temperature was 5.6 ± 0.8°C (range: 3.7-7.5). The mean VIS was 10.2 ± 6.5 (range: 2-32). The number of mild PGD was 5 (14.7%), and moderate PGD was 4 (11.8%). There was no severe PGD. The postoperative EF was 64.3 ± 5.5 (range: 50-78). Mean intubation time was 47.4 ± 64 (range: 8-312, median: 22) h. The mean time of intensive care unit stay was 6.3 ± 5 (range: 2-31, median: 5) days. Two patients required chest revision (5.8%), two patients had lung infection (5.8%). Two patients had a stroke (5.8%). There was no mortality. Using the SherpaPak system during heart transplantation is safe and not associated with significant recipient morbidity. None of the recipients experienced significant PGD and mortality.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to investigate the short-term outcomes of heart transplant patients who underwent SherpaPak™ donor organ preservation.
METHOD
METHODS
We prospectively collected the data of patients who underwent heart transplantation using SherpaPak™ system for donor organ transportation from February 2020 to March 2021. Donor and recipient demographic data, preoperative and postoperative echocardiographic and hemodynamic parameters, total ischemic time and SherpaPak temperatures, vasoactive inotropic scores (VIS), primary graft dysfunction (PGD) status, intensive care unit stay, complications, and mortality during follow-up were assessed.
RESULTS
RESULTS
A total of 39 consecutive heart transplant patients with SherpaPak system were included in the study. The mean donor age was 32.2 ± 6.7 (range: 16-46). The mean recipient age was 57.5 ± 12 (range: 19-73). The mean preoperative ejection fraction (EF) was 23.7 ± 15.4 (range: 5-75). All recipients underwent a standard bicaval technique for orthotopic heart implantation. The mean total ischemic time was 230.1 ± 41 (range: 149-342) min. The mean Sherpa temperature was 5.6 ± 0.8°C (range: 3.7-7.5). The mean VIS was 10.2 ± 6.5 (range: 2-32). The number of mild PGD was 5 (14.7%), and moderate PGD was 4 (11.8%). There was no severe PGD. The postoperative EF was 64.3 ± 5.5 (range: 50-78). Mean intubation time was 47.4 ± 64 (range: 8-312, median: 22) h. The mean time of intensive care unit stay was 6.3 ± 5 (range: 2-31, median: 5) days. Two patients required chest revision (5.8%), two patients had lung infection (5.8%). Two patients had a stroke (5.8%). There was no mortality.
CONCLUSION
CONCLUSIONS
Using the SherpaPak system during heart transplantation is safe and not associated with significant recipient morbidity. None of the recipients experienced significant PGD and mortality.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
732-738Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Radakovic D, Karimli S, Penov K, et al. First clinical experience with the novel cold storage SherpaPak™ system for donor heart transportation. J Thorac Dis. 2020;12(12):7227-7235.
Rees AP, Milani RV, Lavie CJ, Smart FW, Ventura HO. Valvular regurgitation and right-sided cardiac pressures in heart transplant recipients by complete Doppler and color flow evaluation. Chest. 1993;104:82-87.
Wernovsky G, Wypij D, Jonas RA, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation. 1995;92(8):2226-2235.
Kobashigawa J, Zuckermann A, Macdonald P, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant. 2014;33(4):327-340.
Naito N, Funamoto M, Pierson RN, D'Alessandro DA. First clinical use of a novel hypothermic storage system for a long-distance donor heart procurement. J Thorac Cardiovasc Surg. 2020;159(2):e121-e123.
Jahania MS, Sanchez JA, Narayan P, Lasley RD, Mentzer RM Jr. Heart preservation for transplantation: principles and strategies. Ann Thorac Surg. 1999;68:1983-1987.
Nicoara A, Ruffin D, Cooter M, et al. Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors. Am J Transplant. 2018;18(6):1461-1470.
Kobashigawa J, Zuckermann A, Macdonald P, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant. 2014;33(4):327-340.
Yamazaki Y, Oba K, Matsui Y, Morimoto Y. Vasoactive-inotropic score as a predictor of morbidity and mortality in adults after cardiac surgery with cardiopulmonary bypass. J Anesth. 2018;32(2):167-173.
Chan JL, Kobashigawa JA, Aintablian TL, et al. Characterizing predictors and severity of vasoplegia syndrome after heart transplantation. Ann Thorac Surg. 2018;105(3):770-777.
Yansouni CP, Dendukuri N, Liu G, et al. Positive cultures of organ preservation fluid predict postoperative infections in solid organ transplantation recipients. Infect Control Hosp Epidemiol. 2012;33:672-680.
Oriol I, Sabe N, Càmara J, et al. The impact of culturing the organ preservation fluid on solid organ transplantation: a prospective multicenter cohort study. Open Forum Infect Dis. 2019;6(6):ofz180. doi:10.1093/ofid/ofz18